Abstract:To the Editor: Plasmacytoid dendritic cells (pDCs) represent a subset of dendritic cells. There are two distinct forms of neoplasms derived from pDCs; the one is blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the other is mature pDCs proliferation coexisted with myeloid tumors. The mature pDCs in myeloid tumor are characterized by a lineage-negative human leukocyte antigen (HLA)-DR+ CD56− CD123+ CD11c− immunophenotype. Here, we describe an 83-year-old man who developed acute myeloid leukemia (AML) transferred from primary myelofibrosis (PMF) coexisted with monoclonal gammopathy of undetermined significance (MGUS) and mature pDCs proliferation; however, the immunophenotype results of bone marrow (BM) showed positive CD56 expression. An 83-year-old male patient presented with pancytopenia in June 2016. Immunofixation electrophoresis revealed the IgG κ monoclonal immunoglobulin zone, and M protein quantitative value was 1.68 g/L. The BM aspirate was dry tap, and BM blood could only be attained for morphological analysis. Teardrop-like red blood cells could be seen in the BM morphology. Pathology of BM biopsy suggested that myelofibrosis with grade three. Gene screening suggested JAK2V617 gene mutation. Pathological results of left inguinal lymph node biopsy suggested lymphadenosis, with immunophenotypic characteristics of CD20+ CD3+ CD30−. Thus, the lymphoproliferative disease was excluded, and the patient was diagnosed as PMF coexisted with MGUS. Supportive therapy by blood transfusion was given. From January 2017, BM morphology suggested that blast cells gradually increased to 46%, and dendritic cells were visible. Flow cytometry of the BM in April 2017 suggested that immature granulocytes and monoblast cells accounted for 12.5% and 14.1%, respectively, and abnormal pDCs accounted for 2.25%, with immunophenotypic characteristics of CD123+ HLA-DRst+ CD13dim+ CD11bdim+ CD56+ CD4+ BDCA4+ BDCA2−. A diffuse distribution of immature cells was shown in BM biopsy. The patient was diagnosed as AML with pDCs proliferations. He refused chemotherapy, and only supportive treatments were given. He died of pneumonia in July 2017. The overall survival from diagnose was only 3 months. It is unambiguous that the diagnosis of the patient is AML transferred from PMF coexisted with MGUS. What is the reason of pDCs proliferation in the BM? Is it BPDCN or mature pDCs proliferation coexisted with myeloid tumor? A highly suspected diagnosis of BPDCN can be made when skin lesions exist, four antigens among CD4, CD56, CD123, TCL1, and CD303 are expressed by neoplastic cells and myeloid/lymphoid system specific markers such as CD117, MPO, CD20, and CD3 are negative.[1] This patient did not have skin lesions and the immunophenotypic characteristic of BPDCN. Mature pDCs proliferation coexisted with myeloid tumors is rare and affects predominantly male individuals (75%) with a median age of 69 years. Prognosis is usually poor, that is mainly due to the evolution of the myeloid neoplasm rather than expansion of pDCs. These mature pDCs show largely the same immunoprofile as their reactive counterparts, CD123, BDCA2, and TCL1 positive, but occasionally aberrantly express CD2, CD5, CD7, CD10, CD13, CD14, CD15, and CD33. CD56 is usually negative. Several cases with positive CD56 are summed in Supplementary Table 1.[23] We suspect that the advanced age and giving up chemotherapy may contribute to the poor prognosis of the patient reported here. The expression of CD56 suggests that the pDCs in these patients might be derived from monoblast cells.Supplementary Table 1: Clinical information in nine cases of CD56+ pDCs proliferation associated with myeloid tumorSupplementary information is linked to the online version of the paper on the Chinese Medical Journal website. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understand that his name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Mature Plasmacytoid Dendritic Cells Associated with Acute Myeloid Leukemia Show Similar Genetic Mutations and Expression Profiles to Leukemia Cells.

Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells.

Plasmacytoid Dendritic Cells Proliferation Coexisted with Acute Myeloid Leukemia

Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm.

Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid

PNC¯27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML)

Plasmacytoid dendr itic cell expansion in myeloid neoplasms: A novel distinct subset of myeloid neoplasm?

The study of dendritic cells derived from acute myeloid leukemia cells]

Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion

Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia.

Flow Cytometry Profiling of Plasmacytoid Dendritic Cell Neoplasms

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells

Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation

Unveiling the Tempest: Dermal Plasmacytoid Dendritic Cell Proliferation as the Harbinger of Acute Myeloid Leukemia

C/Ebpa Gene Mutation and C/Ebpa Promoter Hypermethylation in Acute Myeloid Leukemia with Normal Cytogenetics.

A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1‐negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia‐related

A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia

Features of Non-Activation Dendritic State and Immune Deficiency in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia

NPM1-mutated Acute Myeloid Leukemia of Monocytic or Myeloid Origin Exhibit Distinct Immunophenotypes.